NEW YORK, June 8, 2026 /PRNewswire/ -- The All Stars Project, Inc. (ASP) announced the launch of its new Artistic Advisory Council (Council), composed...
BASKING RIDGE, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- All customers with telephone numbers with the 347/718/917/929 area codes should be aware of the introduction of the new 465 area code. Beginning June 18, 2026, customers ordering new telephone lines or services in the boroughs of the Bronx, Brooklyn, Queens, Staten Island as well as the Marble Hill section of Manhattan may be assigned numbers using the new 465 area code.
The collaboration builds the first digital twin of a stellarator fusion power plant and leverages world leading AI, physics, and engineering for the U.S. Department of Energy’s Genesis Mission
EDMONTON, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX:MRD), an Alberta-based real estate development and asset management company, announced today that the Toronto Stock Exchange has accepted its notice of intention to make a normal course issuer bid through the facilities of the TSX and on alternative trading systems including: Alpha ATS, Omega ATS, Pure Trading, CHI-X Canada, CX2 and MATCH Now (Triact Canada).
COLOGNE, Germany, June 8, 2026 /PRNewswire/ -- AutoFull, a well-known brand of professional esports furniture, has announced its partnership with the IEM Cologne Major 2026,...
HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...
GEORGE TOWN, Cayman Islands, June 08, 2026 (GLOBE NEWSWIRE) -- Toobit, the award-winning global cryptocurrency exchange, today announces the addition of Stellar (XLM) to its high-yield Fixed Earn series, offering traders an opportunity to capture 60% APR on their staked assets.
Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% of respondents say they're completely prepared for the scale of AI...
Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6